LoginSignup
image de profil
Tenbagger2024
@Tenbagger2024
3Sem.·

The new Novo Nordisk 🙈

$KRYS (-0,08 %)

However, earnings and profit growth are somewhat better than at Novo.


"Buy the dip"

Small additional purchase

04.08
Krystal Biotech logo
Krystal Biotech
Acheté x5 à 117,50 €
587,50 €
10
17 Commentaires
image de profil
K@TechNav
3Sem.
Sehr gute Margen! Wow

Gross Margin 93.37%
Operating Margin 42.26%
Pretax Margin 46.98%
Profit Margin 40.85%
EBITDA Margin 42.81%
EBIT Margin 42.26%
FCF Margin 36.00%
•
2
•
image de profil
Tenbagger2024@Tenbagger2024
3Sem.
@TechNav
My dear,
That's what I'm saying.
Take a look at the EbiT margin at $CORT.
It increases by 10% every year.
••
image de profil
Memo0606@Memo0606
3Sem.
just a little better ? 😂
••
image de profil
Maximilian@Max095
3Sem.
Why the massive collapse today?
••
image de profil
Tenbagger2024@Tenbagger2024
3Sem.
@Max095
It's in my first post.
One was below the estimates
•
1
•
image de profil
Maximilian@Max095
3Sem.
@Tenbagger2024 Thank you. $BNTX could perhaps also be a good alternative. I have a lot in the pipeline for the future.
••
image de profil
Tenbagger2024@Tenbagger2024
3Sem.
@Max095
I'm well supplied for now.
Going to other sectors.
•
1
•
image de profil
Tenbagger2024@Tenbagger2024
3Sem.
@Max095 Good morning my dear,
$ALSTI I find it interesting, you can take a look.
•
1
•
image de profil
Maximilian@Max095
3Sem.
@Tenbagger2024 Thank you :)
••
image de profil
TomTurboInvest@TomTurboInvest
3Sem.
I've never even looked at it. What do they have in the pipeline? They are still quite small in terms of turnover.
••
image de profil
Tenbagger2024@Tenbagger2024
3Sem.
@TomTurboInvest
Approvals in Japan and Europe are still pending. The growth rates are in double figures
•
1
•
image de profil
MrStonkss@MrStonkss
3Sem.
What happens to sales and shares if or when other pipeline projects fail due to regulatory requirements or do not achieve the expected market penetration?

Krystal is currently heavily dependent on a single commercialized product, and a clinical or regulatory setback could wipe out most of the current growth in a very short time.

Is the current valuation with a P/E ratio of over 25 and a market capitalization of around USD 4 bn justified if the company does not yet have a broad, diversified product base or is the market simply paying for the hope of future blockbusters?
••
image de profil
Memo0606@Memo0606
2Sem.
is the bottom in?
••
image de profil
Tenbagger2024@Tenbagger2024
2Sem.
@Memo0606 oh dear, difficult to say.
And when 🍊 rumbles again, it goes down again.
••
image de profil
Memo0606@Memo0606
2Sem.
@Tenbagger2024 but now 🤓
•
2
•
image de profil
Tenbagger2024@Tenbagger2024
2Sem.
@Memo0606
Are you buying more?
•
1
•
image de profil
Memo0606@Memo0606
2Sem.
@Tenbagger2024 unfortunately no more money for it
•
1
•
Participez à la conversation
S'inscrireConnexion